SGLT2 inhibitors and GLP-1 receptor agonists exhibit renoprotective effects in patients with CKD with and without diabetes.

Nearly 16% of American adults—that's close to one in six—now has diabetes, according to the latest data from the U.S. Centers ...

Novo Nordisk said on Wednesday it was aware of reports of 10 deaths and 100 hospitalisations of people who had taken compounded copies of its weight-loss and diabetes drugs. U.S. regulations allow ...

Sotagliflozin is an oral dual sodium-glucose co-transporter types 1 and 2 (SGLT1/SGLT2) inhibitor. The FDA panel voted against the approval of sotagliflozin for patients with type 1 diabetes and ...

Novo Nordisk said on Wednesday it is aware of 10 deaths and 100 hospitalizations resulting from people taking compounded copies of its weight-loss and diabetes drugs, and the CEO said he is alarmed by ...

Drugs for diabetic kidney disease treatment have greatly expanded, allowing research and consensus on their optimal use.